# Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

> **NCT03230318** · PHASE2 · COMPLETED · sponsor: **Basilea Pharmaceutica** · enrollment: 148 (actual)

## Conditions studied

- Intrahepatic Cholangiocarcinoma
- Combined Hepatocellular and Cholangiocarcinoma

## Interventions

- **DRUG:** derazantinib

## Key facts

- **NCT ID:** NCT03230318
- **Lead sponsor:** Basilea Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-28
- **Primary completion:** 2022-10-25
- **Final completion:** 2022-10-25
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2023-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03230318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03230318, "Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03230318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*